Epothilone ZK-219477 in Treating Patients With Recurrent Glioblastoma

Summary

RATIONALE: Drugs used in chemotherapy, such as epothilone ZK-219477, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well epothilone ZK-219477 works in treating patients with recurrent glioblastoma.

Timeline

Start

2006-12

Primary completion

2007-08

Completion

—

Outcome

Missed primary endpoint

paper No objective responses were seen. The progression-free survival (PFS) rate at 6 months was 6.7% PMID 21321091 ↗

paper No evidence of relevant clinical antitumor activity against recurrent glioblastoma could be detected. PMID 21321091 ↗

Publications

• Results Stupp R, Tosoni A, Bromberg JEC, Hau P, Campone M, Gijtenbeek J, Frenay M, Breimer L, Wiesinger H, Allgeier A, van den Bent MJ, Bogdahn U, van der Graaf W, Yun HJ, Gorlia T, Lacombe D, Brandes AA. Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. Ann Oncol. 2011 Sep;22(9):2144-2149. doi: 10.1093/annonc/mdq729. Epub 2011 Feb 14.
• Results Stupp R, Tosoni W, Taal W, et al.: Phase II trial of the epothilone analog sagopilone (ZK219477; ZK EPO) in patients with recurrent glioblastoma: initial report of the EORTC study 26061. [Abstract] J Clin Oncol 26 (Suppl 15): A-2015, 2008.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sagopilone	Small molecule	16 mg/m2	Intravenous

Indications